[HTML][HTML] Effects of tocilizumab on adults with COVID-19 pneumonia: A meta-analysis
CC Chen, YP Yang, HL Tsai, TH Tung - Frontiers in medicine, 2022 - frontiersin.org
CC Chen, YP Yang, HL Tsai, TH Tung
Frontiers in medicine, 2022•frontiersin.orgBackground Coronavirus disease-2019 (COVID-19), a worldwide disaster, has already
affected lots of people. Effective care and therapy are currently being evaluated in full swing.
Purpose Our purpose was to investigate the effects of tocilizumab, an interleukin-6 receptor
inhibitor, on treatment of adult patients with COVID-19 pneumonia. Data Sources, Study
Selection, and Data Extraction We conducted a meta-analysis and searched for relevant
studies on Pubmed, Embase, and the Cochrane Library without restrictions on language …
affected lots of people. Effective care and therapy are currently being evaluated in full swing.
Purpose Our purpose was to investigate the effects of tocilizumab, an interleukin-6 receptor
inhibitor, on treatment of adult patients with COVID-19 pneumonia. Data Sources, Study
Selection, and Data Extraction We conducted a meta-analysis and searched for relevant
studies on Pubmed, Embase, and the Cochrane Library without restrictions on language …
Background
Coronavirus disease-2019 (COVID-19), a worldwide disaster, has already affected lots of people. Effective care and therapy are currently being evaluated in full swing.
Purpose
Our purpose was to investigate the effects of tocilizumab, an interleukin-6 receptor inhibitor, on treatment of adult patients with COVID-19 pneumonia.
Data Sources, Study Selection, and Data Extraction
We conducted a meta-analysis and searched for relevant studies on Pubmed, Embase, and the Cochrane Library without restrictions on language from inception until February 1, 2021. Fifteen studies were included for this meta-analysis. Two authors independently selected and screened these studies, assessed the quality of included studies, and extracted related information.
Results
Fifteen studies were included in this meta-analysis. The main studies showed that tocilizumab was associated with lower mortality (risk ratio = 0.62, 95% confidence interval = 0.46–0.83; and hazard ratio = 0.61, 95% confidence interval = 0.51–0.72). Using tocilizumab might also affect biochemistry indicators (lowered C-reactive protein and ferritin, increased lymphocyte count).
Conclusion
These current bodies of evidence could indicate that early use of tocilizumab was associated with lower mortality in adult patients with COVID-19. Early use of tocilizumab could reduce the mortality rate of adult patients with COVID-19 without obvious fatal side effects, which may be a treatment option in patients with COVID-19 pneumonia.
Systematic Review Registration
The study protocol was registered on PROSPERO (ID:242811).
Frontiers